Development of bioartificial liver system using a fluidized-bed bioreactor

Hwang, Yongha; Kim, Y.I; Lee, J.G; Kim, J.W; Chung, Jung-Hwa

doi:10.1016/s0041-1345(00)01695-x

Cited by 11 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Different cell sources and materials have been investigated since the pioneering work by Dixit et al (1992). Focusing only on alginate-based materials, the encapsulated cells used are mainly of primary murine [105][106][107][108][109][110][111][112][113][114][115][116][117][118][119][120] or porcine [121][122][123][124][125] origin or from hu-man cell lines [51,112,[126][127][128][129][130][131][132][133][134][135][136][137][138], the most popular being HepG2/ C3A. Very few studies have reported the encapsulation of primary human hepatocytes [139][140][141][142].…”

Section: Hepatic Substitutesmentioning

confidence: 99%

Alginate-Based Cell Microencapsulation for Tissue Engineering and Regenerative Medicine

Pandolfi

Pereira

Dufresne

et al. 2017

CPD

View full text Add to dashboard Cite

Increasing numbers of requests for transplantable organs and their scarcity has led to a pressing need to find alternative solutions to standard transplantation. An appealing but challenging proposal came from the fields of tissue engineering and regenerative medicine, the purpose of which is to build tissues/organs from scratch in the laboratory and use them as either permanent substitutes for direct implantation into the patient's body, or as temporary substitutes to bridge patients until organ regeneration or transplantation. Using bioartificial constructs requires administration of immunosuppressant therapies to prevent rejection by the recipient. Microencapsulation has been identified as promising technology for immunoisolating biological materials from immune system attacks by the patient. It is based on entrapping cellular material within a spherical semipermeable polymeric scaffold. This latter defines the boundary between the internal native-like environment and the external "aggressive" one. The scaffold thus acts like a selective filter that makes possible an appropriate supply of nutrients and oxygen to the cellular constructs, while blocking the passage for adverse molecules. Alginate, which is a natural polymer, is the main biomaterial used in this context. Its excellent properties and mild gelation ability provide suitable conditions for supporting viability and preserving the functionalities of the cellular- engineered constructs over long periods. Although much remains to be done before bringing microencapsulated constructs into clinical practice, an increasing number of applications for alginate-based microencapsulation in numerous medical areas confirm the considerable potential for this technology in providing a cure for transplant in patients that excludes immunosuppressive therapies.

show abstract

Section: Hepatic Substitutesmentioning

confidence: 99%

Alginate-Based Cell Microencapsulation for Tissue Engineering and Regenerative Medicine

Pandolfi

Pereira

Dufresne

et al. 2017

CPD

View full text Add to dashboard Cite

show abstract

“…However, the microcapsules could get deformed or broken due to their poor stiffness and high bed pressure drop, resulting in undesired bed clogging and hepatocytes release [5]. Subjecting microcapsules to a fluidized bed seems a promising means to avoid these problems referred to above [18]. Nevertheless, little density difference between plasma and microcapsules causes large void volume in fluidized bed even at low flow rate.…”

Section: Introductionmentioning

confidence: 99%

Development of a bioreactor based on magnetically stabilized fluidized bed for bioartificial liver

Dèng

Chen

Zhang

et al. 2015

Bioprocess Biosyst Eng

View full text Add to dashboard Cite

Bioartificial liver (BAL) based on microcapsules has been proposed as a potential treatment for acute liver failure. The bioreactors used in such BAL are usually expected to achieve sufficient flow rate and minimized void volume for effective application. Due to the superiorities in bed pressure drop and operation velocity, magnetically stabilized fluidized beds (MSFBs) show the potential to serve as ideal microcapsule-based bioreactors. In the present study, we attempted to develop a microcapsule-based MSFB bioreactor for bioartificial liver device. Compared to conventional-fluidized bed bioreactors, the bioreactor presented here increased perfusion velocity and decreased void volume significantly. Meanwhile, the mechanical stability as well as the immunoisolation property of magnetite microcapsules were well maintained during the fluidization. Besides, the magnetite microcapsules were found no toxicity to cell survival. Therefore, our study might provide a novel approach for the design of microcapsule-based bioartificial liver bioreactors.

show abstract

“…Microencapsulated hepatocytes have been successfully used in cell transplantation and bioartificial liver support system for liver function replacement [8][9][10][11]. Fluidized-bed bioreactor has been shown to have a significant effect on preventing the increase of serum ammonia and intracranial pressure in the acute liver failure model of pig [12][13][14][15][16][17]. In our lab, fluidized-bed BLADs (Fig.…”

Section: Introductionmentioning

confidence: 99%

Fluidized-bed bioartificial liver assist devices (BLADs) based on microencapsulated primary porcine hepatocytes have risk of porcine endogenous retroviruses transmission

et al. 2010

View full text Add to dashboard Cite

show abstract

Development of bioartificial liver system using a fluidized-bed bioreactor

Cited by 11 publications

References 8 publications

Alginate-Based Cell Microencapsulation for Tissue Engineering and Regenerative Medicine

Alginate-Based Cell Microencapsulation for Tissue Engineering and Regenerative Medicine

Development of a bioreactor based on magnetically stabilized fluidized bed for bioartificial liver

Fluidized-bed bioartificial liver assist devices (BLADs) based on microencapsulated primary porcine hepatocytes have risk of porcine endogenous retroviruses transmission

Contact Info

Product

Resources

About